Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company’s clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, including IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Metrics to compare | IMNM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIMNMPeersSector | |
|---|---|---|---|---|
P/E Ratio | −10.8x | −3.8x | −0.6x | |
PEG Ratio | −0.21 | −0.16 | 0.00 | |
Price/Book | 9.1x | 2.9x | 2.6x | |
Price / LTM Sales | 249.2x | 119.4x | 3.3x | |
Upside (Analyst Target) | 60.1% | 102.3% | 44.9% | |
Fair Value Upside | Unlock | −9.2% | 5.6% | Unlock |